Details of Drug

Details of Drug

 Drug General Information (ID: D0293)
  Drug Name
Ceftibuten
  Drug Type Small molecule
  Drug Synonymous
CETB; Cedax; Ceftem; Ceftibutene; Ceftibuteno; Ceftibutenum; Cephem; Ceprifran; Isocef; Keimax; Antibiotic 7432S; S 7432; Sch 39720; Cedax (TN); Ceftibutene [INN-French]; Ceftibuteno [INN-Spanish]; Ceftibutenum [INN-Latin]; Cephalosporin 7432-S; Cis-Ceftibutin; Cis-ceftibuten; Sch-39720; Trans-Ceftibuten; Ceftibuten(USAN/INN); Ceftibuten [USAN:INN:BAN]; (+)-(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7432-S; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-3,4-didehydrocepham-4-carboxylic acid
    Click to Show/Hide
  Disease Class CA20: Bronchitis
  Therapeutic Class Antibiotics
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C15H14N4O6S2
  InChI 1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1
  InChIKey UNJFKXSSGBWRBZ-BJCIPQKHSA-N
  Canonical SMILES C1C=C(N2C(S1)C(C2=O)NC(=O)C(=CCC(=O)O)C3=CSC(=N3)N)C(=O)O
  External Link
Pubchem ID 5282242
CAS Number 97519-39-6
CHEBI ID 3510
TTD ID D05JDR
VARIDT ID DR00537

Drug-Drug Interaction Network
  Sunburst Graph
AM001  Affected gastrointestinal absorption
AM003  Affected organization distribution
AM005  Affected excretion pathways
AM006  Pharmacodynamic additive effects
AM007  Pharmacodynamic antagonistic effects
BM002  Altered intestinal flora
BM014  Interference of cell/tissue uptake
BM028  Competitive inhibition of renal tubular secretion
BM031  Increased renal excretion (Unspecific)
BM050  Increased risk of bleeding
BM100  Antagonize the effect of vaccine/toxoid
BM107  Attenuated pharmacological effects (Unspecific)
  Relation Graph
 Full list of drugs interacting with Ceftibuten
      Affected gastrointestinal absorption
   Altered intestinal flora Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1094
 
Mycophenolate mofetil
 
C23H31NO7
 
5281078 
Moderate    Inter Info   
[27], [28]
D1095
 
Mycophenolic acid
 
C17H20O6
 
446541 
Moderate    Inter Info   
[27], [28]
      Affected organization distribution
   Interference of cell/tissue uptake Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1817
 
Indium In-111 oxyquinoline
 
C27H18InN3O3
 
16685037 
Moderate    Inter Info   
[17]
      Affected excretion pathways
   Competitive inhibition of renal tubular secretion Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1341
 
Probenecid
 
C13H19NO4S
 
4911 
Moderate    Inter Info   
[29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56]
   Increased renal excretion (Unspecific) Drug Num:  4
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0217
 
Bumetanide
 
C17H20N2O5S
 
2471 
Moderate    Inter Info   
[9], [10], [11], [12], [13], [14], [15], [16]
D0613
 
Etacrynic acid
 
C13H12Cl2O4
 
3278 
Moderate    Inter Info   
[9], [10], [13]
D0704
 
Furosemide
 
C12H11ClN2O5S
 
3440 
Moderate    Inter Info   
[9], [10], [11], [12], [13], [14], [15], [16]
D1611
 
Torasemide
 
C16H20N4O3S
 
41781 
Moderate    Inter Info   
[9], [10], [13]
      Pharmacodynamic additive effects
   Increased risk of bleeding Drug Num:  3
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0087
 
Anisindione
 
C16H12O3
 
2197 
Moderate    Inter Info   
[5], [6], [7]
D0481
 
Dicoumarol
 
C19H12O6
 
54676038 
Moderate    Inter Info   
[5], [6], [7]
D1711
 
Warfarin
 
C19H16O4
 
54678486 
Moderate    Inter Info   
[5], [6], [7]
      Pharmacodynamic antagonistic effects
   Antagonize the effect of vaccine/toxoid Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1914
 
Typhoid vaccine (live)
 
NA
 
NA
Major    Inter Info   
[1], [2], [3]
D1693
 
Vibrio cholerae CVD 103-HgR strain live antigen (live)
 
NA
 
NA
Major    Inter Info   
[4]
   Attenuated pharmacological effects (Unspecific) Drug Num:  6
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0145
 
Balsalazide
 
C17H15N3O6
 
54585 
Moderate    Inter Info   
[8]
D1287
 
Picosulfuric acid
 
C18H15NO8S2
 
5243 
Moderate    Inter Info   
[18], [19], [20]
D0313
 
Chloramphenicol
 
C11H12Cl2N2O5
 
5959 
Moderate    Inter Info   
[21], [22], [23]
D0606
 
Estradiol
 
C18H24O2
 
5757 
Moderate    Inter Info   
[24], [25], [26]
D0619
 
Ethinylestradiol
 
C20H24O2
 
5991 
Moderate    Inter Info   
[24], [25], [26]
D1011
 
Mestranol
 
C21H26O2
 
6291 
Moderate    Inter Info   
[24], [25], [26]
References
1 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2 UK government "Typhoid.".
3 American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association (1994).
4 Product Information. Vaxchora (cholera vaccine, live). PaxVax, Miami, FL.
5 Product Information. Suprax (cefixime). Lupin Pharmaceuticals Inc, Baltimore, MD.
6 Wood T, Johnson K, Naylor S, Weinshilboum R "Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia." Drug Metab Dispos 30 (2002): 1123-1128
7 Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976): 91-3
8 Product Information. Colazal (balsalazide) Salix Pharmaceuticals, Palo Alto, CA.
9 Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J "Pharmacokinetic interactions of ceftazidime and frusemide." J Chemother 7 Suppl (1995): 107-10. [PMID: 8904125]
10 Dodds MG, Foord RD "Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine." Br J Pharmacol 40 (1970): 227-36. [PMID: 5492895]
11 Korn A, Eichler HG, Gasic S "A drug interaction study of ceftriaxone and frusemide in healthy volunteers." Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4. [PMID: 3733274]
12 Lawson DH, Macadam RF, Singh H, et al "Effect of furosemide on antibiotic-induced renal damage in rats." J Infect Dis 126 (1972): 593-600. [PMID: 4664116]
13 Norrby R, Stenqvist K, Elgefors B "Interaction between cephaloridine and furosemide in man." Scand J Infect Dis 8 (1976): 209-12. [PMID: 968459]
14 Simpson IJ "Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine." N Z Med J 74 (1971): 312-5. [PMID: 5289757]
15 Tilstone WJ, Semple PF, Lawson DH, Boyle JA "Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin." Clin Pharmacol Ther 22 (1977): 389-94. [PMID: 902451]
16 Trollfors B, Norrby R, Kristianson K, Nilsson NJ "Effects on renal function of treatment with cefoxitin alone or in combination with furosemide." Scand J Infect Dis 13 (1978): 73-7. [PMID: 356182]
17 Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111). GE Healthcare, Princeton, NJ.
18 Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate). Ferring Pharmaceuticals Inc, Tarrytown, NY.
19 MHRA. Medicines and Healthcare Regulatory Agency (general site Reference).
20 Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate). Ferring Pharmaceuticals Inc, Tarrytown, NY.
21 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA."
22 Asmar BI, Prainito M, Dajani AS "Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone." Antimicrob Agents Chemother 32 (1988): 1375-8
23 Brown TH, Alford RH "Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae." Antimicrob Agents Chemother 25 (1984): 405-7
24 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
25 Barnett ML "Inhibition of oral contraceptive effectiveness by concurrent antibiotic administration." J Periodontol 56 (1985): 18-20. [PMID: 3882930]
26 King VJ "OC failure rates and oral antibiotics." J Fam Pract 45 (1997): 104-5. [PMID: 9267366]
27 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
28 Product Information. Myfortic (mycophenolic acid). Novartis Pharmaceuticals, East Hanover, NJ.
29 Brown G, Zemcov SJ, Clarke AM "Effect of probenecid on cefazolin serum concentrations." J Antimicrob Chemother 31 (1993): 1009-11. [PMID: 8360120]
30 Brown GR "Cephalosporin-probenecid drug interactions." Clin Pharmacokinet 24 (1993): 289-300. [PMID: 8491057]
31 Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD "Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels." J Antimicrob Chemother 40 (1997): 903-6. [PMID: 9462447]
32 Griffith RS, Black HR, Brier GL, Wolny JD "Effect of probenecid on the blood levels and urinary excretion of cefamandole." Antimicrob Agents Chemother 11 (1977): 809-12. [PMID: 879735]
33 Ings RM, Reeves DS, White LO, et al "The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination." J Pharmacokinet Biopharm 13 (1985): 121-42. [PMID: 4057054]
34 Kercsmar CM, Stern RC, Reed MD, et al "Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response." J Antimicrob Chemother 12 (1983): 289-95. [PMID: 6352634]
35 Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ "Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination." Antimicrob Agents Chemother 33 (1989): 356-61. [PMID: 2729930]
36 DiPiro JT, Welage LS, Levine BA, et al. Single-dose cefmetazole versus multiple dose cefoxitin for prophylaxis in abdominal surgery.?J Antimicrob Chemother. 1989;23 Suppl D:71-77. [PMID: 2722725]
37 LeBel M, Paone RP, Lewis GP "Effect of probenecid on the pharmacokinetics of ceftizoxime." J Antimicrob Chemother 12 (1983): 147-55. [PMID: 6311785]
38 Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W "Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime." Antimicrob Agents Chemother 20 (1981): 567-75. [PMID: 6275776]
39 Marino EL, Dominguez-Gil A "The pharmacokinetics of cefadroxil associated with probenecid." Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8. [PMID: 6795136]
40 LeBel M, Paone RP, Lewis GP. Effect of probenecid on the pharmacokinetics of ceftizoxime.?J Antimicrob Chemother. 1983;12(2):147-155. [PMID: 6311785]
41 Mischler TW, Sugerman AA, Willard DA, et al "Influence of probenecid and food on the bioavailability of cephradine in normal male subjects." J Clin Pharmacol 14 (1974): 604-11. [PMID: 4436447]
42 Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ "Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting." Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7. [PMID: 7889965]
43 Pitkin D, Dubb J, Actor P, et al "Kinetics and renal handling of cefonicid." Clin Pharmacol Ther 30 (1981): 587-93. [PMID: 7297018]
44 Product Information. Ceftin (cefuroxime). Glaxo Wellcome, Research Triangle Park, NC.
45 Product Information. Fortaz (ceftazidime). Glaxo Wellcome, Research Triangle Park, NC.
46 Product Information. Omnicef (cefdinir). Parke-Davis, Morris Plains, NJ.
47 Product Information. Rocephin (ceftriaxone). Roche Laboratories, Nutley, NJ.
48 Product Information. Tazicef (ceftazidime). SmithKline Beecham, Philadelphia, PA.
49 Product Information. Vantin (cefpodoxime proxetil). Pharmacia and Upjohn, Kalamazoo, MI.
50 Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP "The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers." Br J Clin Pharmacol 11 (1981): 353-9. [PMID: 7259928]
51 Santoro J, Agarwal BN, Martinelli R, et al "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978): 951-4. [PMID: 677862]
52 Shukla UA, Pittman KA, Barbhaiya RH "Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers." J Clin Pharmacol 32 (1992): 725-31. [PMID: 1487562]
53 Spina SP, Dillon EC "Effect of chronic probenecid therapy on cefazolin serum concentrations." Ann Pharmacother 37 (2003): 621-4. [PMID: 12708933]
54 Stoeckel K, Trueb V, Dubach UC, McNamara PJ "Effect of probenecid on the elimination and protein binding of ceftriaxone." Eur J Clin Pharmacol 34 (1988): 151-6. [PMID: 3383987]
55 Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB "Effect of orally administered probenecid on the pharmacokinetics of cefoxitin." Antimicrob Agents Chemother 17 (1980): 847-55. [PMID: 7396472]
56 Welling PG, Dean S, Selen A, et al "Probenecid: an unexplained effect on cephalosporin pharmacology." Br J Clin Pharmacol 8 (1979): 491-5. [PMID: 508557]